SMI
11.871,32
PKT
-0,20
PKT
±0,00
%
Werbung
Analysen zu SMI-Werten
Datum | Rating | Analyst | |
---|---|---|---|
29.03.05 | Roche Buy | Sarasin Research | |
24.03.05 | Roche Sector Outperform | Vontobel | |
24.03.05 | Swisscom Neutral | Sarasin Research | |
22.03.05 | UBS Buy | Merrill Lynch | |
22.03.05 | ABB (Asea Brown Boveri) Overweight | JP Morgan | |
22.03.05 | Roche Buy | Sarasin Research | |
23.03.05 | UBS Neutral | Merrill Lynch | |
21.03.05 | Holcim Neutral | Sarasin Research | |
21.03.05 | Novartis Neutral | Sarasin Research | |
21.03.05 | ABB (Asea Brown Boveri) Neutral | Sarasin Research | |
22.03.05 | Geberit Reduce | Helvea | |
22.03.05 | Swisscom Neutral | Helvea | |
22.03.05 | Holcim Accumulate | Helvea | |
21.03.05 | Novartis Kaufen | Helaba Trust | |
22.03.05 | ABB (Asea Brown Boveri) Accumulate | Helvea | |
22.03.05 | Novartis Accumulate | Helvea | |
21.03.05 | Geberit Market Outperform | Vontobel | |
21.03.05 | Novartis Neutral | Sarasin Research | |
17.03.05 | UBS Buy | Helvea | |
18.03.05 | ABB (Asea Brown Boveri) Overweight | Lehman Brothers | |
18.03.05 | Geberit Reduce | Helvea | |
16.03.05 | Swiss Life Underperformer | LB Rheinland-Pfalz | |
17.03.05 | Roche Buy | Helvea | |
16.03.05 | Kühne + Nagel International Neutral | Sarasin Research | |
17.03.05 | Novartis Outperform | Goldman Sachs | |
16.03.05 | Swiss Life Sell | Merck Finck & Co | |
17.03.05 | Roche In-Line | Goldman Sachs | |
15.03.05 | UBS Overweight | JP Morgan | |
15.03.05 | Kühne + Nagel International Market Perform | Vontobel | |
15.03.05 | UBS Overweight | JP Morgan | |
15.03.05 | Logitech Neutral | Sarasin Research | |
14.03.05 | Swiss Life Marketperformer | LB Rheinland-Pfalz | |
14.03.05 | Kühne + Nagel International Neutral | Sarasin Research | |
14.03.05 | Swiss Life Outperform | HypoVereinsbank | |
16.03.05 | Kühne + Nagel International Neutral | Helvea | |
14.03.05 | Swiss Life Buy | M.M. Warburg | |
15.03.05 | Swiss Life Akkumulieren | Nord LB | |
11.03.05 | Swisscom Neutral | Sarasin Research | |
11.03.05 | Novartis Buy | Helvea | |
17.03.05 | UBS Outperform | Credit Suisse First Boston |
* Die angezeigten Realtime Kurse sind indikativ und nicht die offiziellen Börsenkurse. Die Kursdaten können eventuell vom tatsächlichen Marktpreis abweichen.